SEC Form SC 13G filed by AN2 Therapeutics Inc.

SEC Form SC 13G filed by AN2 Therapeutics Inc.

Recent Analyst Ratings for $ANTX

$ANTX Market Insights

$ANTX Analyst Ratings

$ANTX Insider Purchases

$ANTX SEC Filings

$ANTX Press Releases

$ANTX Insider Trading

$ANTX Large Ownership Changes

$ANTX Financials

$ANTX Leadership Updates

Recent Analyst Ratings for
$ANTX

$ANTX
Market Insights

$ANTX
Analyst Ratings

$ANTX
Insider Purchases

$ANTX
SEC Filings

$ANTX
Press Releases

$ANTX
Insider Trading

$ANTX
Large Ownership Changes

$ANTX
Financials

$ANTX
Leadership Updates

Chat with this insight

Live Market Insights

Leerink Partners Upgrades AN2 Therapeutics to Outperform

12 Health Care Stocks Moving In Friday's After-Market Session

Evercore ISI Group Maintains In-Line on AN2 Therapeutics, Lowers Price Target to $2

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

AN2 Therapeutics downgraded by Evercore ISI

AN2 Therapeutics downgraded by Leerink Partners with a new price target

AN2 Therapeutics upgraded by Leerink Partners with a new price target

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Large owner Leonard Braden Michael bought $1,560,000 worth of shares (1,500,000 units at $1.04) (SEC Form 4)

AN2 Therapeutics Inc. filed SEC Form 8-K: Leadership Update

SEC Form 8-A12B filed by AN2 Therapeutics Inc.

AN2 Therapeutics Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

Fastest customizable press release news feed in the world

AN2 Therapeutics Receives Continuation Grant to Discover Novel Boron Based Therapies for Tuberculosis (caused by Mycobacterium tuberculosis) and Malaria

AN2 Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

AN2 Therapeutics Adopts Limited Duration Stockholder Rights Plan

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Strategy Officer Prior Stephen David was granted 10,125 shares, increasing direct ownership by 40% to 35,342 units (SEC Form 4)

Officer Eizen Joshua M was granted 31,500 shares, increasing direct ownership by 33% to 126,335 units (SEC Form 4)

New insider Prior Stephen David claimed ownership of 25,217 shares (SEC Form 3)

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by AN2 Therapeutics Inc.

Amendment: SEC Form SC 13G/A filed by AN2 Therapeutics Inc.

Amendment: SEC Form SC 13G/A filed by AN2 Therapeutics Inc.

Live finance-specific insights

Live Leadership Updates

AN2 Therapeutics Adopts Limited Duration Stockholder Rights Plan

AN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlights

Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results

Brii Biosciences Provides Latest Clinical Development and Corporate Updates

AN2 Therapeutics Appoints Maggie FitzPatrick to Its Board of Directors

4/10/24 4:44:57 PM ET

$ANTX

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ANTX alert in real time by email

SC 13G 1 d816254dsc13g.htm SC 13G SC 13G

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. )*

AN2 Therapeutics, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

37326105

(CUSIP Number)

April 3, 2024

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☒ Rule 13d-1(c)

☐ Rule 13d-1(d)

*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 37326105

(1)

Consists of 707,879 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P.

(2)	Based on 29,770,375 shares of Common Stock outstanding on March 22, 2024, as set forth in the Issuer’s Form 10-K as filed with the SEC on March 29, 2024.

CUSIP No. 37326105

(1)

(2)	Based on 29,770,375 shares of Common Stock outstanding on March 22, 2024, as set forth in the Issuer’s Form 10-K as filed with the SEC on March 29, 2024.

CUSIP No. 37326105

(1)

(2)	Based on 29,770,375 shares of Common Stock outstanding on March 22, 2024, as set forth in the Issuer’s Form 10-K as filed with the SEC on March 29, 2024.

CUSIP No. 37326105

(1)

Consists of 437,900 shares of Common Stock held directly by Frazier Life Sciences Public Overage Fund, L.P. FHMLSP Overage, L.P. is the general partner of Frazier Life Sciences Public Overage Fund, L.P. and FHMLSP Overage, L.L.C. is the general partner of FHMLSP Overage, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP Overage, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Overage Fund, L.P.

(2)	Based on 29,770,375 shares of Common Stock outstanding on March 22, 2024, as set forth in the Issuer’s Form 10-K as filed with the SEC on March 29, 2024.

CUSIP No. 37326105

(1)

(2)	Based on 29,770,375 shares of Common Stock outstanding on March 22, 2024, as set forth in the Issuer’s Form 10-K as filed with the SEC on March 29, 2024.

CUSIP No. 37326105

(1)

(2)	Based on 29,770,375 shares of Common Stock outstanding on March 22, 2024, as set forth in the Issuer’s Form 10-K as filed with the SEC on March 29, 2024.

CUSIP No. 37326105

(1)

Consists of 60,933 shares of Common Stock held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick J. Heron and James N. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P.

(2)	Based on 29,770,375 shares of Common Stock outstanding on March 22, 2024, as set forth in the Issuer’s Form 10-K as filed with the SEC on March 29, 2024.

CUSIP No. 37326105

(1)

(2)	Based on 29,770,375 shares of Common Stock outstanding on March 22, 2024, as set forth in the Issuer’s Form 10-K as filed with the SEC on March 29, 2024.

CUSIP No. 37326105

(1)

(2)	Based on 29,770,375 shares of Common Stock outstanding on March 22, 2024, as set forth in the Issuer’s Form 10-K as filed with the SEC on March 29, 2024.

CUSIP No. 37326105

(1)

Consists of 282,177 shares of Common Stock held directly by Frazier Life Sciences XI, L.P. FHMLS XI, L.P. is the general partner of Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P. Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XI, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XI, L.P.

(2)	Based on 29,770,375 shares of Common Stock outstanding on March 22, 2024, as set forth in the Issuer’s Form 10-K as filed with the SEC on March 29, 2024.

CUSIP No. 37326105

(1)

(2)	Based on 29,770,375 shares of Common Stock outstanding on March 22, 2024, as set forth in the Issuer’s Form 10-K as filed with the SEC on March 29, 2024.

CUSIP No. 37326105

(1)

(2)	Based on 29,770,375 shares of Common Stock outstanding on March 22, 2024, as set forth in the Issuer’s Form 10-K as filed with the SEC on March 29, 2024.

CUSIP No. 37326105

(1)

Consists of (i) 707,879 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P., (ii) 437,900 shares of Common Stock held directly by Frazier Life Sciences Public Overage Fund, L.P., (iii) 60,933 shares of Common Stock held directly by Frazier Life Sciences X, L.P., and (iv) 282,177 shares of Common Stock held directly by Frazier Life Sciences XI, L.P. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P. FHMLSP Overage, L.P. is the general partner of Frazier Life Sciences Public Overage Fund, L.P. and FHMLSP Overage, L.L.C. is the general partner of FHMLSP Overage, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP Overage, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Overage Fund, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick J. Heron and James N. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P. FHMLS XI, L.P. is the general partner of Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P. Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XI, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XI, L.P.

(2)	Based on 29,770,375 shares of Common Stock outstanding on March 22, 2024, as set forth in the Issuer’s Form 10-K as filed with the SEC on March 29, 2024.

CUSIP No. 37326105

(1)

(2)	Based on 29,770,375 shares of Common Stock outstanding on March 22, 2024, as set forth in the Issuer’s Form 10-K as filed with the SEC on March 29, 2024.

CUSIP No. 37326105

(1)

Consists of (i) 707,879 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P., and (ii) 437,900 shares of Common Stock held directly by Frazier Life Sciences Public Overage Fund, L.P. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P. FHMLSP Overage, L.P. is the general partner of Frazier Life Sciences Public Overage Fund, L.P. and FHMLSP Overage, L.L.C. is the general partner of FHMLSP Overage, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP Overage, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Overage Fund, L.P.

(2)	Based on 29,770,375 shares of Common Stock outstanding on March 22, 2024, as set forth in the Issuer’s Form 10-K as filed with the SEC on March 29, 2024.

CUSIP No. 37326105

(1)

(2)	Based on 29,770,375 shares of Common Stock outstanding on March 22, 2024, as set forth in the Issuer’s Form 10-K as filed with the SEC on March 29, 2024.

CUSIP No. 37326105

(1)

(2)	Based on 29,770,375 shares of Common Stock outstanding on March 22, 2024, as set forth in the Issuer’s Form 10-K as filed with the SEC on March 29, 2024.

Item 1(a).

Name of Issuer: AN2 Therapeutics, Inc.

Item 1(b).

Address of Issuer’s Principal Executive Offices: 1800 El Camino Real, Suite D, Menlo Park, CA 94027

Item 2(a).

Name of Person Filing:

The entities and persons filing this statement (collectively, the “Reporting Persons”) are:

Frazier Life Sciences Public Fund, L.P. (“FLSPF”)

FHMLSP, L.P.

FHMLSP, L.L.C.

Frazier Life Sciences Public Overage Fund, L.P. (“FLSPOF”)

FHMLSP Overage, L.P.

FHMLSP Overage, L.L.C.

Frazier Life Sciences XI, L.P. (“FLS XI”)

FHMLS XI, L.P.

FHMLS XI, L.L.C.

Frazier Life Sciences X, L.P. (“FLS X”)

FHMLS X, L.P.

FHMLS X, L.L.C.

James N. Topper (“Topper”)

Patrick J. Heron (“Heron”)

Albert Cha (“Cha”)

James Brush (“Brush”)

Daniel Estes (“Estes” and together with Topper, Heron, Cha and Brush, the “Members”)

Item 2(b).

Address of Principal Business Office or, if none, Residence:

The address and principal business office of the Reporting Persons is:

c/o Frazier Life Sciences Management, L.P.

1001 Page Mill Rd, Building 4, Suite B

Palo Alto, CA 94304

Item 2(c).

Citizenship:


Entities:	FLSPF	-	Delaware, U.S.A.
	FHMLSP, L.P.	-	Delaware, U.S.A.
	FHMLSP, L.L.C.	-	Delaware, U.S.A.
	FLSPOF	-	Delaware, U.S.A.
	FHMLSP Overage, L.P.	-	Delaware, U.S.A.
	FHMLSP, L.L.C.	-	Delaware, U.S.A.
	FLS XI	-	Delaware, U.S.A.
	FHMLS XI, L.P.	-	Delaware, U.S.A.
	FHMLS XI, L.L.C.	-	Delaware, U.S.A.
	FLS X	-	Delaware, U.S.A.
	FHMLS X, L.P.	-	Delaware, U.S.A.
	FHMLS X, L.L.C.	-	Delaware, U.S.A.

Individuals:	Topper	-	United States Citizen
	Heron	-	United States Citizen
	Cha	-	United States Citizen
	Brush	-	United States Citizen
	Estes	-	United States Citizen

Item 2(d).

Title of Class of Securities: Common Stock

Item 2(e).

CUSIP Number: 37326105

Item 3.

If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:


(a)		☐ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);

(b)		☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c)		☐ Insurance company as defined in section 3(a)19) of the Act (15 U.S.C. 78c);

(d)		☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

(e)		☐ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

(f)		☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

(g)		☐ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

(h)		☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)		☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j)		☐ A non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J);

(k)		☐ Group, in accordance with §240.13d–1(b)(1)(ii)(K).

		If filing as a non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J), please specify the type of institution: ____

Item 4.

Ownership

Provide the following information regarding the aggregate number and percentage of the class of securities of the Issuer identified in Item 1.

(a)

Amount Beneficially Owned: See Row 9 of cover page for each Reporting Person.

(b)

Percent of Class: See Row 11 of cover page for each Reporting Person

(c)

Number of shares as to which the person has:

(i)

Sole power to vote or to direct the vote: See Row 5 of cover page for each Reporting Person.

(ii)

Shared power to vote or to direct the vote: See Row 6 of cover page for each Reporting Person.

(iii)

Sole power to dispose or to direct the disposition of: See Row 7 of cover page for each Reporting Person.

(iv)

Shared power to dispose or to direct the disposition of: See Row 8 of cover page for each Reporting Person.

Item 5.

Ownership of 5 Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐.

Item 6.

Ownership of More than 5 Percent on Behalf of Another Person

Not applicable.

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

Not applicable.

Item 8.

Identification and Classification of Members of the Group

Each member of the group is identified on Exhibit A to this Schedule 13G amendment.

Item 9.

Notice of Dissolution of a Group

Not applicable.

Item 10.

Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.


Date: April 10, 2024						FRAZIER LIFE SCIENCES PUBLIC FUND, L.P.
						By: FHMLSP, L.P., its General Partner
						By: FHMLSP, L.L.C., its General Partner

						By: /s/ Steve R. Bailey
						Steve R. Bailey, Chief Financial Officer

Date: April 10, 2024						FHMLSP, L.P.
						By: FHMLSP, L.L.C., its General Partner

						By: /s/ Steve R. Bailey
						Steve R. Bailey, Chief Financial Officer

Date: April 10, 2024						FHMLSP, L.L.C.

						By: /s/ Steve R. Bailey
						Steve R. Bailey, Chief Financial Officer

Date: April 10, 2024						FRAZIER LIFE SCIENCES PUBLIC OVERAGE FUND, L.P.
						By: FHMLSP Overage, L.P., its General Partner
						By: FHMLSP Overage, L.L.C., its General Partner

						By: /s/ Steve R. Bailey
						Steve R. Bailey, Chief Financial Officer

Date: April 10, 2024						FHMLSP OVERAGE, L.P.
						By FHMLSP Overage, L.L.C., its General Partner

						By: /s/ Steve R. Bailey
						Steve R. Bailey, Chief Financial Officer

Date: April 10, 2024						FHMLSP OVERAGE, L.L.C.

						By: /s/ Steve R. Bailey
						Steve R. Bailey, Chief Financial Officer

Date: April 10, 2024						FRAZIER LIFE SCIENCES XI, L.P.
						By: FHMLS XI, L.P., its General Partner
						By: FHMLS XI, L.L.C., its General Partner

						By: /s/ Steve R. Bailey
						Steve R. Bailey, Chief Financial Officer

Date: April 10, 2024						FHMLS XI, L.P.
						By: FHMLS XI, L.L.C., its General Partner

						By: /s/ Steve R. Bailey
						Steve R. Bailey, Chief Financial Officer


Date: April 10, 2024	FHMLS XI, L.L.C.

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: April 10, 2024	FRAZIER LIFE SCIENCES X, L.P.
	By: FHMLS X, L.P., its General Partner
	By: FHMLS X, L.L.C., its General Partner

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: April 10, 2024	FHMLS X, L.P.
	By: FHMLS X, L.L.C., its General Partner

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: April 10, 2024	FHMLS X, L.L.C.

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: April 10, 2024	By:	*
		James N. Topper

Date: April 10, 2024	By:	*
		Patrick J. Heron

Date: April 10, 2024	By:	**
		Albert Cha

Date: April 10, 2024	By:	**
		James Brush

Date: April 10, 2024	By:	***
		Daniel Estes

Date: April 10, 2024	By:	/s/ Steve R. Bailey
		Steve R. Bailey, as Attorney-in-Fact

*	This Schedule 13G was executed by Steve R. Bailey on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which was filed with the SEC on March 29, 2016.

**	This Schedule 13G was executed by Steve R. Bailey on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which was filed with the SEC on August 16, 2021.

***	This Schedule 13G was executed by Steve R. Bailey on behalf of the individual listed above pursuant to a Power of Attorney, a copy of which was filed with the SEC on April 18, 2022.

Exhibit Index

Exhibit A - Agreement regarding filing of joint Schedule 13G.

Get the next $ANTX alert in real time by email

Date	Price Target	Rating	Analyst
8/9/2024		In-line → Underperform	Evercore ISI
8/9/2024	$5.00 → $1.00	Outperform → Market Perform	Leerink Partners
7/3/2024	$5.00	Market Perform → Outperform	Leerink Partners
4/2/2024	$6.00	Mkt Perform → Mkt Outperform	JMP Securities
2/13/2024	$23.00 → $7.00	Outperform → Market Perform	Leerink Partners
2/12/2024	$25.00 → $7.00	Outperform → In-line	Evercore ISI
2/12/2024		Outperform → Perform	Oppenheimer
2/12/2024		Mkt Outperform → Mkt Perform	JMP Securities

Names of Reporting Persons

Frazier Life Sciences Public Fund, L.P.

Check the Appropriate Box if a Member of a Group (see instructions)

(a) ☐ (b) ☒

SEC USE ONLY

Citizenship or Place of Organization

Delaware